MGC Pharma is joining a global Covid-19 World Health Organisation (WHO) taskforce to map and assess research and clinical trials aimed at halting the global pandemic.
The move comes as the Perth-based, ASX-listed medicinal cannabis company announced an expansion of its clinical trial of ArtemiC in Covid-19 patients to India after receiving ethics approval.
The trial is assessing the safety and efficacy of the natural anti-inflammatory formulation (based on Artemisinin and Curcumin) on the respiratory systems of Covid-19 patients. Tests are already underway in Israel.
Co-founder and managing director of MGC Pharma Roby Zomer said: “We have expanded the patient recruitment process for our phase two clinical trial to India where there is still a large number of new Covid-19 cases being reported on a daily basis.”
At the time of writing, MGC Pharma shares are trading at 2.2 cents, up nine per cent since the market opened.